Select Language

HLA-A*2402 & B2M & EBV BRLF1 (TYPVLEEMF)

HLA-A*2402 & B2M & EBV BRLF1 (TYPVLEEMF) Product List

Product Category
Protein (1)
Product Status
Launched (1)
Species
Human (1)
Tag
His Tag & Avi Tag (1)
Conjugate
Unconjugated (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
HLF-H52E5	Human	HEK293	Unconjugated Human HLA-A*24:02&B2M&EBV BRLF1 (TYPVLEEMF) Complex Protein (Monomer, MALS verified)

Total: 1

HLA-A*2402 & B2M & EBV BRLF1 (TYPVLEEMF) Background

This is a recombinant protein complex of HLA-A*24:02 presenting an immunodominant 9-mer peptide (TYPVLEEMF) derived from the Epstein-Barr virus (EBV) immediate-early transactivator BRLF1. HLA-A*24:02 is a common class I allele, and this peptide is a well-characterized target for CD8⁺ T cells in EBV-seropositive individuals, making the complex a valuable tool for studying antigen-specific T cell responses in viral immunity and immunotherapies.

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
CHM-2101	CDH17-CAR T; CHM-2101; CHM2101; CHM-2101 CAR-T cells	Phase 2 Clinical	University Of Pennsylvania	Stomach Neoplasms; Pancreatic Neoplasms; Neuroendocrine Tumors; Colorectal Neoplasms; Gastrointestinal Neoplasms	Details
BI-905711	BI-905711	Phase 1 Clinical	Boehringer Ingelheim Gmbh	Pancreatic Neoplasms; Cholangiocarcinoma; Gastrointestinal Neoplasms	Details
ARB-202	ARB-202	Phase 1 Clinical	Arbele Corp	Liver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastrointestinal Neoplasms	Details